Senya signed an R&D collaboration agreement with the University of Edinburgh to explore the potential applications of STX-001, its lead compound, in nephrology.

Under the agreement, Senya will fund the research and retain ownership of its outcomes, while the University of Edinburgh will contribute preclinical and clinical expertise.